⌘K
Loading ticker…
As of 2026-08-24, Elicio Therapeutics, Inc. Common Stock (ELTX) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 27. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.7%, relative volume 1.11×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ELTX is in a stage 4 downtrend, week 8. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -16.3% / -64.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ELTX is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $4M notional.
Held by 3 ETFs · $6M across latest filings · largest weight 0.02% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $4M | — |
| VXFVanguard Extended Market ETF | 0.00% | $1M | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ELTX Jan avg: 10.26% median: -4.52% win: 33% σ: 66.15% n: 3 2023-06-05 → 2026-07-31 | ELTX Feb avg: 17.48% median: -7.73% win: 33% σ: 46.30% n: 3 2023-06-05 → 2026-07-31 | ELTX Mar avg: 14.54% median: -17.71% win: 33% σ: 63.05% n: 3 2023-06-05 → 2026-07-31 | ELTX Apr avg: 0.09% median: -0.66% win: 33% σ: 20.60% n: 3 2023-06-05 → 2026-07-31 | ELTX May avg: 13.51% median: 7.72% win: 67% σ: 30.95% n: 3 2023-06-05 → 2026-07-31 | ELTX Jun avg: -38.67% median: -47.81% win: 25% σ: 31.46% n: 4 2023-06-05 → 2026-07-31 | ELTX Jul avg: 6.31% median: 13.28% win: 75% σ: 26.19% n: 4 2023-06-05 → 2026-07-31 | ELTX Aug avg: -10.94% median: -13.51% win: 33% σ: 17.14% n: 3 2023-06-05 → 2026-07-31 (current) | ELTX Sep avg: 12.85% median: 3.89% win: 100% σ: 16.92% n: 3 2023-06-05 → 2026-07-31 | ELTX Oct avg: -16.96% median: -15.31% win: 0% σ: 3.05% n: 3 2023-06-05 → 2026-07-31 | ELTX Nov avg: 3.92% median: 0.75% win: 67% σ: 14.25% n: 3 2023-06-05 → 2026-07-31 | ELTX Dec avg: 6.95% median: 0.20% win: 67% σ: 25.95% n: 3 2023-06-05 → 2026-07-31 |